BR0112989A - Vacina direcionada contra uma infecção, genoma viral recombinante, uso de um genoma, e, método para limitar os riscos de um indivìduo de adquirir ou manifestar completamente uma doença causada por uma infecção - Google Patents

Vacina direcionada contra uma infecção, genoma viral recombinante, uso de um genoma, e, método para limitar os riscos de um indivìduo de adquirir ou manifestar completamente uma doença causada por uma infecção

Info

Publication number
BR0112989A
BR0112989A BR0112989-9A BR0112989A BR0112989A BR 0112989 A BR0112989 A BR 0112989A BR 0112989 A BR0112989 A BR 0112989A BR 0112989 A BR0112989 A BR 0112989A
Authority
BR
Brazil
Prior art keywords
infection
genome
recombinant viral
disease caused
risk
Prior art date
Application number
BR0112989-9A
Other languages
English (en)
Other versions
BRPI0112989B1 (pt
Inventor
Frank Fehler
Klaus Osterrieder
Original Assignee
Lohmann Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Animal Health Gmbh filed Critical Lohmann Animal Health Gmbh
Publication of BR0112989A publication Critical patent/BR0112989A/pt
Publication of BRPI0112989B1 publication Critical patent/BRPI0112989B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"VACINA DIRECIONADA CONTRA UMA INFECçãO, GENOMA VIRAL RECOMBINANTE, USO DE UM GENOMA, E, MéTODO PARA LIMITAR OS RISCOS DE UM INDIVìDUO DE ADQUIRIR OU MANIFESTAR COMPLETAMENTE UMA DOENçA CAUSADA POR UMA INFECçãO". A invenção diz respeito ao campo dos chamados herpesvírus associados com a célula hospedeira tais como o vírus semelhante á doença de Marek (MDV) de aves domésticas e do vírus da Varicela Zoster (VZV) do ser humano e à vacinação contra a doença causada por estes virus. A invenção fornece uma vacina direcionada contra uma infecção causada por um herpesvírus que está essencialmente associado com a célula hospedeira compreendendo um genoma viral recombinante derivado do dito herpesvírus, o dito genoma permitindo a recombinação essencialmente livre da dita célula hospedeira.
BRPI0112989A 2000-08-03 2001-08-01 genoma viral recombinante BRPI0112989B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202757A EP1178111A1 (en) 2000-08-03 2000-08-03 Vaccination against host cell-associated herpesviruses
PCT/EP2001/008893 WO2002012288A2 (en) 2000-08-03 2001-08-01 Vaccination against host cell-associated herpesviruses

Publications (2)

Publication Number Publication Date
BR0112989A true BR0112989A (pt) 2003-09-09
BRPI0112989B1 BRPI0112989B1 (pt) 2015-09-08

Family

ID=8171884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0112989A BRPI0112989B1 (pt) 2000-08-03 2001-08-01 genoma viral recombinante

Country Status (24)

Country Link
US (1) US9073979B2 (pt)
EP (2) EP1178111A1 (pt)
JP (1) JP4313036B2 (pt)
KR (1) KR100633180B1 (pt)
CN (2) CN102151333A (pt)
AT (1) ATE412055T1 (pt)
AU (2) AU9171601A (pt)
BR (1) BRPI0112989B1 (pt)
CA (1) CA2417923C (pt)
CZ (1) CZ303904B6 (pt)
DE (1) DE60136278D1 (pt)
EA (1) EA010721B1 (pt)
ES (1) ES2315306T3 (pt)
HR (1) HRP20030147B1 (pt)
HU (1) HU228262B1 (pt)
IL (2) IL154250A0 (pt)
MX (1) MXPA03001027A (pt)
NO (1) NO332621B1 (pt)
NZ (1) NZ524066A (pt)
PL (1) PL207958B1 (pt)
PT (1) PT1307565E (pt)
UA (1) UA84667C2 (pt)
WO (1) WO2002012288A2 (pt)
ZA (1) ZA200300842B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses
CA2558586A1 (en) * 2004-03-05 2005-09-15 The Research Foundation For Microbial Diseases Of Osaka University Recombinant varicella-zoster virus
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP3590533A1 (en) 2009-05-22 2020-01-08 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
RS54933B1 (sr) 2009-12-21 2016-10-31 Brigham & Womens Hospital Inc Vakcine herpes simpleks virusa
EP2643014A4 (en) * 2010-11-24 2015-11-11 Genocea Biosciences Inc HERPES SIMPLEX TYPE 2 VIRUS VACCINES: COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
CA2851658C (en) * 2011-10-21 2022-03-15 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
CA2885693C (en) * 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN105561303B (zh) * 2015-12-30 2019-04-05 暨南大学 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
CN105641692A (zh) * 2015-12-30 2016-06-08 暨南大学 单纯疱疹病毒ⅰ型基因重组减毒活疫苗及其制备方法
CN105597095A (zh) * 2015-12-30 2016-05-25 暨南大学 一种应用微载体培养Vero细胞制备基因缺失减毒疫苗的方法
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2019020480A1 (en) * 2017-07-24 2019-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
BR112020012162A2 (pt) * 2017-12-20 2020-11-24 Intervet International B.V. diluente aprimorado para vacina contra alfa-herpesvírus associado à célula
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) * 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
GB8821441D0 (en) 1988-09-13 1988-10-12 Animal Health Inst Viral vectors
EP0486106A3 (en) 1990-11-16 1992-12-23 Akzo N.V. Marek's disease virus vaccine
AU657144B2 (en) * 1991-07-09 1995-03-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Recombinant Marek's disease virus, process for preparing the same and vaccine containing the same
JP3675569B2 (ja) 1995-04-28 2005-07-27 日本ゼオン株式会社 組み換えウイルス及びそれよりなるワクチン
KR19990028766A (ko) 1995-07-07 1999-04-15 나카노 가쓰히꼬 마렉 질환 바이러스 유전자 및 마렉 질환 예방용 백신에서그의 용도
US6306387B1 (en) * 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
AUPP684998A0 (en) * 1998-10-30 1998-11-26 Murdoch Institute for Research into Birth Defects Limited, The A method of recombination and agents useful for same
EP1038952A3 (en) 1998-12-09 2001-06-27 Pfizer Products Inc. Processes for preparation of Marek's Disease Virus using continuous avian cell lines
US6410222B1 (en) * 1998-12-14 2002-06-25 Juridical Foundation The Chemosero-Therapeutic Research Institute In ovo vaccination of marek's disease type I virus
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
EP1178111A1 (en) 2000-08-03 2002-02-06 Lohmann Animal Health GmbH & Co. KG Vaccination against host cell-associated herpesviruses

Also Published As

Publication number Publication date
CZ303904B6 (cs) 2013-06-19
CN102151333A (zh) 2011-08-17
NO332621B1 (no) 2012-11-19
CZ2003324A3 (cs) 2003-06-18
HRP20030147A2 (en) 2005-04-30
JP2004505993A (ja) 2004-02-26
NO20030524D0 (no) 2003-02-03
HUP0302664A3 (en) 2004-10-28
PT1307565E (pt) 2009-01-28
EP1307565A2 (en) 2003-05-07
IL154250A0 (en) 2003-09-17
MXPA03001027A (es) 2004-02-26
UA84667C2 (ru) 2008-11-25
NZ524066A (en) 2004-11-26
WO2002012288A3 (en) 2002-04-11
DE60136278D1 (de) 2008-12-04
KR20030036657A (ko) 2003-05-09
CA2417923A1 (en) 2002-02-14
IL154250A (en) 2013-07-31
AU2001291716B8 (en) 2002-02-18
US9073979B2 (en) 2015-07-07
EP1178111A1 (en) 2002-02-06
CA2417923C (en) 2010-06-29
ATE412055T1 (de) 2008-11-15
PL365190A1 (en) 2004-12-27
AU9171601A (en) 2002-02-18
PL207958B1 (pl) 2011-02-28
AU2001291716B2 (en) 2007-06-07
WO2002012288A2 (en) 2002-02-14
HRP20030147B1 (en) 2011-10-31
HUP0302664A2 (hu) 2003-11-28
ZA200300842B (en) 2004-04-30
KR100633180B1 (ko) 2006-10-11
EA200300215A1 (ru) 2003-08-28
NO20030524L (no) 2003-04-03
ES2315306T3 (es) 2009-04-01
US20030165537A1 (en) 2003-09-04
HU228262B1 (en) 2013-02-28
CN1503843A (zh) 2004-06-09
BRPI0112989B1 (pt) 2015-09-08
EA010721B1 (ru) 2008-10-30
JP4313036B2 (ja) 2009-08-12
EP1307565B1 (en) 2008-10-22

Similar Documents

Publication Publication Date Title
BR0112989A (pt) Vacina direcionada contra uma infecção, genoma viral recombinante, uso de um genoma, e, método para limitar os riscos de um indivìduo de adquirir ou manifestar completamente uma doença causada por uma infecção
Arvin et al. Human herpesviruses: biology, therapy, and immunoprophylaxis
García et al. Genomic sequence analysis of the United States infectious laryngotracheitis vaccine strains chicken embryo origin (CEO) and tissue culture origin (TCO)
AR010102A1 (es) VACUNA VIVA RECOMBINANTE AVIARIA QUE COMPRENDE CoMO VECTOR UN VIRUS ILTV QUE COMPRENDE Y EXPRESA AL MENOS UNA SECUENCIA NUCLEOTíDICAHETERoLOGA
EP1298139A3 (en) Avian herpes virus-based recombinant infectious bursal disease vaccine
Spatz et al. Comparative genomic sequence analysis of the Marek’s disease vaccine strain SB-1
Sarkar et al. Equine herpesvirus-1 suppresses type-I interferon induction in equine endothelial cells
Yu et al. Newcastle disease virus vectored infectious laryngotracheitis vaccines protect commercial broiler chickens in the presence of maternally derived antibodies
Field et al. Herpesvirus latency and therapy—from a veterinary perspective
CN102089423A (zh) 通过表达ⅰ型干扰素反应的抑制剂来增强来自基于病毒的疫苗载体的转基因表达
AU6313000A (en) Recombinant hsv-1 and live viral vaccines
de la Fuente et al. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model
Fernández‐Parrado et al. Monkeypox vaccine: Special considerations for dermatologic patients.
Bonin et al. Mouse neurotropic recombinants of influenza A viruses
MX9605139A (es) Linea celular de pollo, sostenible, infectada con el virus de la enfermedad de marek.
Tenser et al. Neuronal control of herpes simplex virus latency
Mayer et al. Dexamethasone-induced reactivation of bovine herpesvirus type 5 latent infection in experimentally infected rabbits results in a broader distribution of latent viral DNA in the brain
Sun et al. Attenuation of a recombinant Marek's disease virus lacking the meq oncogene and evaluation on its immune efficacy against Marek's disease virus
DE68929000D1 (de) AUF DEM gB-PROTEIN DES MAREK'S DISEASE VIRUS (MDV) BASIERENDE, REKOMBINANTE IMPFSTOFFE
Mariappan et al. Marek’s disease virus
BR0304750A (pt) Mutante de herpesvìrus bovino tipo 5, vacina dirigida contra a encefalite viral bovina (bhv-s) e o vìrus rábico e método de preparação da vacina
Aricò et al. MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68
Stewart Of mice and men: murine gammaherpesvirus 68 as a model
EA030866B1 (ru) Модифицированный вирус болезни марека и вакцины на его основе
Griffiths The herpesvirus family in the 21st century

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C07K 14/055

Ipc: A61K 39/255 (2006.01), C12N 15/38 (2006.01)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved